Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter [Yahoo! Finance]
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: Yahoo! Finance
provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, I am pleased to present our mid-year update for our unaudited first half results of 2024, highlighting Daxor Corporation's remarkable progress and financial performance. Our commitment to innovation in blood volume analysis (BVA) technology continues to drive growth and create value for our stakeholders. Financial Highlights: I am thrilled to report that our financial position has strengthened significantly. Our Net Asset Value (NAV) has increased to $6.75 per share, up from $6.33 per share at this time last year. More impressively, our unaudited revenue for the first half of 2024 has more than doubled compared to the same period in 2023, marking a year-on-year growth exceeding 100%. This substantial increase is attributed to rising sales from existing customers and the addition of fourteen new accounts so far this year, already surpa
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24GlobeNewswire
- Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewswire
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic DeviceGlobeNewswire
- Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024GlobeNewswire
DXR
Analyst Actions
- 9/9/24 - Ascendiant Capital
DXR
Sec Filings
- 11/21/24 - Form NPORT-P
- 9/10/24 - Form N-PX
- 8/29/24 - Form NPORT-P
- DXR's page on the SEC website